Accessibility Menu
Biolase logo

Biolase(OTC) BIOL

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)-100%
5 YearN/A
1 Year+0%
1 Month+0%
N/A
Biolase last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-31
Biolase stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-18
1 month+0%USD 0.002026-07-17
3 month+0%USD 0.002026-05-28
Year to date+0%USD 0.002025-12-31
1 year+0%USD 0.002025-08-29
Since inception-100%USD 199,459.831992-11-12

Biolase Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$46.03M

Net Income (TTM)

-$16.04M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 7, 2024

BIOL News

The Fool Looks Ahead

Rick MunarrizNov 9, 2013

Up 25%, the Anti-Dentite's Nightmare Stock Surges

Brenton FlynnFeb 6, 2013

Whoa! What Just Happened to My Stock?

Rich DupreyAug 11, 2011

The Stocks Wall Street Loves

Rich DupreyJul 28, 2011

How to Ride This Crazy Roller-Coaster

Anders BylundJun 26, 2011

3 Stocks Shaking the Market

Rich DupreyApr 7, 2011

Tuesday's Worst Stocks in the World

Tim BeyersNov 7, 2007

Wall Street's Buy List

Rich SmithOct 23, 2007
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biolase

BIOLASE, Inc. is a global leader in the development and distribution of advanced laser systems for dental professionals. The company specializes in innovative technologies that enhance dental procedures, making them more efficient and less invasive for patients.

Products and Services
  • Waterlase all-tissue dental laser systems for precise cutting
  • Diode soft-tissue laser systems for various dental applications
  • Epic Hygiene laser for non-surgical periodontitis treatment
Growth Outlook
  • Recent quarterly revenue of $10.85 million shows strong market demand
  • Gross profit margin improved to 40.39% in Q3 2024
  • Continued investment in R&D to drive product innovation
Financial Highlights
  • Net income of -$1.43 million in Q3 2024, reflecting ongoing operational challenges
  • Cash and cash equivalents of $3.44 million as of September 30, 2024
  • Current ratio of 1.26 indicates adequate short-term financial health
BIOLASE, Inc. operates in the medical devices sector, focusing on dental laser technology. The company has established a strong presence in the dental market, providing tools that enable dental professionals to perform a wide range of procedures with enhanced precision and patient comfort. The recent quarterly performance indicates a solid revenue stream, although challenges remain in achieving profitability. The company continues to invest in research and development, aiming to expand its product offerings and improve operational efficiency. With a focus on innovation and market demand, BIOLASE is positioned to capitalize on growth opportunities in the dental industry.
AI Generated • Aug 20, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

157

CEO

John R. Beaver, CPA

Website

www.biolase.com

Headquarters

Foothill Ranch, CA 92610-2811, US

BIOL Financials

Key Financial Metrics (TTM)

Gross Margin

34.02%

Operating Margin

-36.48%

Net Income Margin

-41.97%

Return on Equity

-888.93%

Return on Capital

-101.55%

Return on Assets

-58.78%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$15.85M

Operating Income

-$13.52M

EBITDA

-$10.97M

Operating Cash Flow

-$13.43M

Capital Expenditure

-$225.00K

Free Cash Flow

-$13.65M

Cash & ST Invst.

$3.44M

Total Debt

$18.69M

Biolase Performance Analysis

Biolase annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 39,188,000N/A
20222022-12-31USD 48,462,00023.7%
20232023-12-31USD 49,164,0001.4%
Biolase sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-3123.5%
Q12024-03-31-24.9%
Q22024-06-3014.1%
Q32024-09-30-6.1%
Biolase annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -282.65N/A
20222022-12-31USD -416.3247.3%
20232023-12-31USD -29.44-92.9%
Biolase sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-3154.8%
Q12024-03-3179.5%
Q22024-06-3076.7%
Q32024-09-3052.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2024YOY CHG

Revenue

$10.85M

-0.7%

Gross Profit

$4.38M

+17.0%

Gross Margin

40.39%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

157

N/A

Net Income

-$1.43M

+68.9%

EBITDA

-$166.00K

+95.1%

Quarterly Fundamentals

Name
Q3 2024YOY CHG

Total Cash

$3.44M

-55.9%

Total Debt

$18.69M

+23.8%

Accounts Receivable

$3.53M

-19.6%

Inventory

$9.87M

-28.6%

Long Term Debt

$211.00K

-98.8%

Short Term Debt

$18.48M

+402.6%

Return on Assets

-58.78%

N/A

Return on Invested Capital

-1.16%

N/A

Free Cash Flow

-$4.51M

-62.9%

Operating Cash Flow

-$4.47M

-72.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PAVMPAVmed Inc.
$5.21+5.89%
INFIQInfinity Pharmaceuticals, Inc.
$0.00+0.00%
WENAAnew Medical, Inc.
$0.73-3.84%
NEPTFNeptune Wellness Solutions Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About BIOL

What is the current price of Biolase?

Biolase is trading at N/A per share.

What is the 52-week range for Biolase?

Over the past 52 weeks, Biolase has traded between N/A and N/A.

How much debt does Biolase have?

As of the most recent reporting period, Biolase reported total debt of $17.46M.

How much cash does Biolase have on hand?

Biolase reported $3.44M in cash and cash equivalents in its most recent financial results.

What is Biolase’s dividend yield?

Biolase does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services